Pharma News, 2022

Johnson & Johnson has secured another regulatory approval for its BCMAxCD3 bispecific antibody for multiple myeloma – Tecvayli – adding to the wide range of therapies available for the blo...

Vanda Pharmaceuticals’ VPO-227 has received FDA’s Orphan Drug designation for the treatment of patients with cholera.

The FDA has granted Fast Track designation to Acumen Pharmaceuticals’ ACU193 for the treatment of patients with early Alzheimer’s disease.

SGLT-2 inhibitors, GLP-1 receptor agonists, and a non-steroidal mineralocorticoid receptor are all showing promise in the prevention and management of diabetic kidney disease. ...

Foralumab, an anti-CD3 monoclonal antibody, has been previously assessed in diseases such as progressive multiple sclerosis and Crohn disease, as well as in patients with mild to moderate COVID-19....

The FDA has granted Priority Review to Daiichi Sankyo’s New Drug Application (NDA) for quizartinib in combination with standard cytarabine and anthracycline induction and standard cytarabine con...

Sumitomo subsidiary Sumitovant has entered into a purchase agreement to acquire all Myovant’s outstanding shares — gaining one promising cancer drug and another for treatment of premenopausal c...

AstraZeneca’s long-troubled cancer immunotherapy tremelimumab has finally secured its first FDA approval, but the regulatory blessing comes in what could be an increasingly competitive tumor typ...

Education and support are critical to getting — and keeping — patients on appropriate therapy. But many oncology patients have gaps in their knowledge of their condition, treatment and existing...

The FDA has approved GSK’s Menveo single vial vaccine for individuals 10 to 55 years old to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W. ...

Eureka Therapeutics has received an Orphan Drug designation for its investigational therapy ET140203 for the treatment of hepatoblastoma, a rare liver tumor that usually occurs in children under f...

Ventatorx Pharmaceuticals’ investigational antibiotic cefepime-taniborbactam has shown promise in a late-stage study for treatment of complicated urinary tract infections. ...